Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of filgotinib, GS-9876, and tirabrutinib in active Sjogren's syndrome
2016-003558-34Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome (4 arms), sponsored by Gilead Sciences. Primary endpoint: Primary efficacy endpoint. Started May 2017; status: completed.
02
Drugs
filgotiniblanraplenibtirabrutinib
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2016-003558-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003558-34.